Fol­low­ing in­flux of cash, Pi­ra­mal in­vests in an­oth­er In­di­an CD­MO; US inks deal with man­u­fac­tur­er of rapid Covid-19 tests

In­di­an CD­MO Ya­pan Bio has land­ed an in­vest­ment from Pi­ra­mal Phar­ma, the com­pa­ny an­nounced, to help en­hance its man­u­fac­tur­ing arm.

Ya­pan pro­vides bi­o­log­ic and vac­cine scale-up and man­u­fac­tur­ing ser­vices, in­clud­ing RNA, DNA, re­com­bi­nant vac­cines, gene ther­a­pies and mon­o­clon­al an­ti­bod­ies. With the in­vest­ment, Pi­ra­mal takes on a 27.78% stake in the com­pa­ny and will help Ya­pan keep up the quick pace of the rapid­ly ex­pand­ing CD­MO space. It will com­bine its an­ti­body drug con­ju­ga­tion ca­pa­bil­i­ties with Pi­ra­mal’s fill-fin­ish ser­vices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER